Summary of Key Points
Mei, a 6-year-old girl with a mild and rare disease, died after participating in the world's first clinical trial using brain base editing. This incident revealed issues such as research teams concealing risks from animal experiments, advancing trials illegally, and papers failing to disclose the death. It also exposed structural flaws in China's cell and gene therapy (CGT) industry: while early exploratory trials (IITs) are prevalent (accounting for 11% globally), confirmatory Phase II/III trials necessary for market approval account for less than 2% (about 11% globally). Many projects stall after publishing their papers, leading to a severe imbalance between academic pursuits and clinical safety as well as industrial transformation. The industry needs to address these shortcomings in areas such as regulation, evaluation systems, and funding to ensure that technology truly benefits patients.
I. The Tragic Story: Overlooked Risks and Hidden Truths
Mei suffered from a non-fatal rare disease, but the Qiu Zilong team used a high-dose viral vector (AAV) for the experiment. The entire process was fraught with violations:
- Ignoring Risk Warnings: Animal experiments showed liver damage in all four rhesus monkeys, and the high-dose group also experienced kidney damage (indicating microvascular risks), yet the team did not inform the family or stop the trial.
- Ethical Approval Violations: The ethics committee approved the plan in January before the safety report for primates was available.
- Hiding the Death: Mei died from thrombotic microvascular disease 7 days after treatment, which the hospital attributed to the therapy. However, the team only mentioned mouse experiments in their subsequent paper published in Nature, completely omitting the human death until the family demanded clarification.
Experts stated, "This trial should not have been conducted" due to the clear risks and the fact that using high-risk therapies for non-fatal diseases offers far less benefit than the potential harm.
II. Industry Imbalance: Prosperous Early Trials, Lack of Later-Stage Translation
China's CGT industry appears active, but it is unbalanced:
- Many Early Trials: China accounts for 11% of global early CGT exploratory trials, significantly higher than other pharmaceutical fields. 94.2% of these trials are initiated by researchers (IITs), which are small in scale and short in duration, making it easy to produce data and publish papers quickly.
- Fewer Later-Stage Trials: Confirmatory Phase II/III trials necessary for market approval account for less than 2% globally. Many projects stop after completing early stages and publishing in top journals, as they require substantial funding (often hundreds of millions), are time-consuming (3-5 years), and carry high failure risks, with limited potential for publications.
In short, we have many laboratory breakthroughs, but few of them lead to actual drug development.
III. The Root Causes of the Imbalance: Paper-Oriented Approaches, Insufficient Funding, and Vague Regulation
Why is this the case?
1. Research Evaluation Based on Papers: Universities and research institutions use top journals to evaluate tenure and fund projects. IITs can quickly produce data labeled as "world-first" or "novative," making it easier to publish in prestigious journals like Nature/Science, while later-stage trials are less likely to generate such impressive papers.
2. Funding Shortages: Later-stage trials are costly; only 25.6% of China's CGT projects rely on industrial capital (compared to nearly 50% overseas), with most relying on research funding, which is insufficient to support these trials.
3. Vague Regulatory Framework: There is a lack of clarity around whether cutting-edge technologies like gene editing should be classified as "drugs" or "medical devices," leading to uncertainty and hesitation among companies to invest in later-stage trials.
IV. The Way Forward: Addressing the Issues Through Systemic Changes and Multi-Stakeholder Collaboration
CGT holds promise for patients with rare diseases, but it must not come at the cost of human lives. Solutions require concerted efforts from various stakeholders:
- Strengthening Regulation: New regulations, such as the "Biomedical New Technology Management Regulations," have clarified the requirements for IITs (e.g., mandatory reporting of adverse events and ongoing ethical reviews), but these need to be effectively implemented. This includes training professionals in ethical review to prevent inexperienced individuals from making decisions.
- Reforming Evaluation Systems: We need to reduce the reliance on papers and include criteria such as whether a technology can be translated into drugs and whether it truly benefits patients in research evaluations.
- Industry Capital Involvement: Encourage companies and investment institutions to fund later-stage trials, for example, by negotiating with healthcare systems and using commercial insurance to reduce financial barriers.
- Researcher Responsibility: Researchers must prioritize patient safety over paper publication.
The ultimate value of technology lies in its ability to safely benefit patients. This tragedy serves as a reminder that the industry must strive for genuine development that puts people's lives first.